Sulanemadlin Completed Phase 1 Trials for Lymphoma / Brain Neoplasm / Solid Tumors / Leukemias Treatment

Indications	Status	Purpose	Phase
DBCOND0006647 (Lymphoma) DBCOND0028149 (Brain Neoplasm) DBCOND0029860 (Solid Tumors) DBCOND0035632 (Leukemias)	Completed	Treatment	1

clinicaltrials.gov Identifier	Title	Drugs
NCT03654716	Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer	Cytarabine (DB00987) Sulanemadlin (DB17285)